Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), Formulation (Cream, Gel, Spray, Patch, and Others) and Distribution Channel (Pharmacies & Drug Stores, e-Commerce, and Retail & Grocery Stores) - Global Opportunity Analysis and Industry Forecast, 2018-2025
- Published Date: 2020-10-18
- Report ID: 3076
- Pages: 275
-
Format:
Pain treatment involves usage of common analgesics or painkillers to reduce and treat body pain. Whenever, these analgesics are applied directly to the skin they are known as topical pain relief medications. These include topical administration of drugs such as non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, tricyclic antidepressants, ketamine, clonidine, opioids, and cannabinoids. Topical pain relief medications exert peripheral effects near the site of application and minimize the pain. Topical formulations used for pain relief include creams, ointments, gels, and newly developed drug-delivery systems, usually transdermal patches. They are mostly available as over-the-counter (OTC) products while some are available through prescription only.
The global topical pain relief market was valued at $7,481 million in 2017, and is projected to reach $13,276 million by 2025 at a CAGR of 7.4% from 2018 to 2025. Increase in prevalence of arthritis is the major factor that contributes towards the growth of the topical pain relief market. Moreover, other factors that fuel the market growth include growth in geriatric population, lesser side effects caused due to use of topical analgesics as compared to oral pain relief, and high demand for topical pain relief by sports players. However, topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that impede the market growth. Conversely, development of online platform for the topical therapeutics and high market potential in untapped emerging economies are expected to provide lucrative opportunities for the market growth.
The global topical pain relief market is segmented into therapeutic class, type, formulation, distribution channel, and region. Based on therapeutic class, the market is divided into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. Based on type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. Based on the formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS
The study provides an in-depth analysis of the global topical pain relief market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key market segments
By Therapeutic Class
Non-opioids
Nonsteroidal anti-inflammatory drug (NSAIDS)
Methyl Salicylate
Capsaicin
Lidocaine
Other Non-opioids
Opioids
Buprenorphine
Fentanyl
By Type
Prescription Pain Relief
Over-the-counter (OTC) Pain Relief
By Formulation
Cream
Gel
Spray
Patch
Others
By Formulation
Pharmacies & Drug Stores
e-Commerce
Retail & Grocery Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Johnson & Johnson
Novartis AG
GlaxoSmithKline Plc.
Pfizer Inc.
Reckitt Benckiser Group Plc.
Sanofi S.A.
Topical BioMedics, Inc.
AdvaCare Pharma
Sun Pharmaceutical Industries Ltd.
Nestle S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Troy Healthcare, LLC
Emami Group
Chattem, Inc.
Exzell Pharma
Performance Health Technologies, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. By Therapeutic Class
1.3.2. By Type
1.3.3. By Formulation
1.3.4. By Distribution Channel
1.3.5. By Region
1.3.6. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines
3.4.2. Restraints
3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief are characterized by unpleasant odor
3.4.3. Opportunities
3.4.3.1. Emergence of online pharmacy
3.4.3.2. Opportunities in emerging economies
3.4.4. Impact analyses
3.5. Patent analysis (2013-2018)
3.5.1. Patent analysis, by year
3.5.2. Patent analysis for U.S., by year
CHAPTER 4: TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Non-opioids
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)
4.2.2.1.1. Market size and forecast, by region
4.2.2.2. Methyl salicylates
4.2.2.2.1. Market size and forecast, by region
4.2.2.3. Capsaicin
4.2.2.3.1. Market size and forecast, by region
4.2.2.4. Lidocaine
4.2.2.4.1. Market size and forecast, by region
4.2.2.5. Other Non-Opioids
4.2.2.5.1. Market size and forecast, by region
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Opioids
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Buprenorphine
4.3.2.1.1. Market size and forecast, by region
4.3.2.2. Fentanyl
4.3.2.2.1. Market size and forecast, by region
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5: TOPICAL PAIN RELIEF MARKET, BY FORMULATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cream
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Gel
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Spray
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Patch
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: TOPICAL PAIN RELIEF MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Prescription pain relief
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Over-the-counter pain relief
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7: TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Pharmacies & drug stores
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. e-Commerce
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
7.4. Grocery stores
7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country
CHAPTER 8: TOPICAL PAIN RELIEF MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. North America topical pain relief market, by country
8.2.2.1. U.S.
8.2.2.1.1. Market size and forecast, by therapeutic class
8.2.2.1.2. Market size and forecast, by formulation
8.2.2.1.3. Market size and forecast, by type
8.2.2.1.4. Market size and forecast, by distribution channel
8.2.2.2. Canada
8.2.2.2.1. Market size and forecast, by therapeutic class
8.2.2.2.2. Market size and forecast, by formulation
8.2.2.2.3. Market size and forecast, by type
8.2.2.2.4. Market size and forecast, by distribution channel
8.2.2.3. Mexico
8.2.2.3.1. Market size and forecast, by therapeutic class
8.2.2.3.2. Market size and forecast, by formulation
8.2.2.3.3. Market size and forecast, by type
8.2.2.3.4. Market size and forecast, by distribution channel
8.2.3. North America market size and forecast, by therapeutic class
8.2.4. North America market size and forecast, by formulation
8.2.5. North America market size and forecast, by type
8.2.6. North America market size and forecast, by distribution channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Europe market size and forecast, by country
8.3.2.1. Germany
8.3.2.1.1. Market size and forecast, by therapeutic class
8.3.2.1.2. Market size and forecast, by formulation
8.3.2.1.3. Market size and forecast, by type
8.3.2.1.4. Market size and forecast, by distribution channel
8.3.2.2. France
8.3.2.2.1. Market size and forecast, by therapeutic class
8.3.2.2.2. Market size and forecast, by formulation
8.3.2.2.3. Market size and forecast, by type
8.3.2.2.4. Market size and forecast, by distribution channel
8.3.2.3. UK
8.3.2.3.1. Market size and forecast, by therapeutic class
8.3.2.3.2. Market size and forecast, by formulation
8.3.2.3.3. Market size and forecast, by type
8.3.2.3.4. Market size and forecast, by distribution channel
8.3.2.4. Italy
8.3.2.4.1. Market size and forecast, by therapeutic class
8.3.2.4.2. Market size and forecast, by formulation
8.3.2.4.3. Market size and forecast, by type
8.3.2.4.4. Market size and forecast, by distribution channel
8.3.2.5. Spain
8.3.2.5.1. Market size and forecast, by therapeutic class
8.3.2.5.2. Market size and forecast, by formulation
8.3.2.5.3. Market size and forecast, by type
8.3.2.5.4. Market size and forecast, by distribution channel
8.3.3. Rest of Europe
8.3.3.1.1. Market size and forecast, by therapeutic class
8.3.3.1.2. Market size and forecast, by formulation
8.3.3.1.3. Market size and forecast, by type
8.3.3.1.4. Market size and forecast, by distribution channel
8.3.4. Europe market size and forecast, by therapeutic class
8.3.5. Europe market size and forecast, by formulation
8.3.6. Europe market size and forecast, by type
8.3.7. Europe market size and forecast, by distribution channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Asia-Pacific market size and forecast, by country
8.4.2.1. Japan
8.4.2.1.1. Market size and forecast, by therapeutic class
8.4.2.1.2. Market size and forecast, by type
8.4.2.1.3. Market size and forecast, by type
8.4.2.1.4. Market size and forecast, by distribution channel
8.4.2.2. China
8.4.2.2.1. Market size and forecast, by therapeutic class
8.4.2.2.2. Market size and forecast, by formulation
8.4.2.2.3. Market size and forecast, by type
8.4.2.2.4. Market size and forecast, by distribution channel
8.4.2.3. India
8.4.2.3.1. Market size and forecast, by therapeutic class
8.4.2.3.2. Market size and forecast, by formulation
8.4.2.3.3. Market size and forecast, by type
8.4.2.3.4. Market size and forecast, by distribution channel
8.4.2.4. Australia
8.4.2.4.1. Market size and forecast, by therapeutic class
8.4.2.4.2. Market size and forecast, by formulation
8.4.2.4.3. Market size and forecast, by type
8.4.2.4.4. Market size and forecast, by distribution channel
8.4.2.5. South Korea
8.4.2.5.1. Market size and forecast, by therapeutic class
8.4.2.5.2. Market size and forecast, by formulation
8.4.2.5.3. Market size and forecast, by type
8.4.2.5.4. Market size and forecast, by distribution channel
8.4.2.6. Rest of Asia-Pacific
8.4.2.6.1. Market size and forecast, by therapeutic class
8.4.2.6.2. Market size and forecast, by formulation
8.4.2.6.3. Market size and forecast, by type
8.4.2.6.4. Market size and forecast, by distribution channel
8.4.3. Asia-Pacific market size and forecast, by therapeutic class
8.4.4. Asia-Pacific market size and forecast, by formulation
8.4.5. Asia-Pacific market size and forecast, by type
8.4.6. Asia-Pacific market size and forecast, by distribution channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. LAMEA market size and forecast, by country
8.5.2.1. Brazil
8.5.2.1.1. Market size and forecast, by therapeutic class
8.5.2.1.2. Market size and forecast, by formulation
8.5.2.1.3. Market size and forecast, by type
8.5.2.1.4. Market size and forecast, by distribution channel
8.5.2.2. Saudi Arabia
8.5.2.2.1. Market size and forecast, by therapeutic class
8.5.2.2.2. Market size and forecast, by formulation
8.5.2.2.3. Market size and forecast, by type
8.5.2.2.4. Market size and forecast, by distribution channel
8.5.2.3. South Africa
8.5.2.3.1. Market size and forecast, by therapeutic class
8.5.2.3.2. Market size and forecast, by formulation
8.5.2.3.3. Market size and forecast, by type
8.5.2.3.4. Market size and forecast, by distribution channel
8.5.2.4. Rest of LAMEA
8.5.2.4.1. Market size and forecast, by therapeutic class
8.5.2.4.2. Market size and forecast, by formulation
8.5.2.4.3. Market size and forecast, by type
8.5.2.4.4. Market size and forecast, by distribution channel
8.5.3. LAMEA market size and forecast, by therapeutic class
8.5.4. LAMEA market size and forecast, by formulation
8.5.5. LAMEA market size and forecast, by type
8.5.6. LAMEA market size and forecast, by distribution channel
CHAPTER 9: COMPANY PROFILES
9.1. AdvaCare Pharma
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio
9.2. GlaxoSmithKline plc.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product Portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments
9.3. Johnson & Johnson
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance
9.4. Nestl S.A.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product Portfolio
9.4.5. Business performance
9.5. Novartis AG
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product Portfolio
9.5.5. Business performance
9.6. Pfizer Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product Portfolio
9.6.5. Business performance
9.7. Reckitt Benckiser Group plc
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product Portfolio
9.7.5. Business performance
9.8. Sanofi
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product Portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sun Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product Portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. Topical BioMedics, Inc.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product Portfolio
9.10.5. Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
